WO2022159319A3 - A porous aluminum nanoparticulate structure - Google Patents
A porous aluminum nanoparticulate structure Download PDFInfo
- Publication number
- WO2022159319A3 WO2022159319A3 PCT/US2022/012224 US2022012224W WO2022159319A3 WO 2022159319 A3 WO2022159319 A3 WO 2022159319A3 US 2022012224 W US2022012224 W US 2022012224W WO 2022159319 A3 WO2022159319 A3 WO 2022159319A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- porous aluminum
- nanoparticulate
- aluminum
- capping agent
- nanoparticulate structure
- Prior art date
Links
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 title abstract 5
- 229910052782 aluminium Inorganic materials 0.000 title abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 abstract 2
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 abstract 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 2
- 229920003169 water-soluble polymer Polymers 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
- 229920000053 polysorbate 80 Polymers 0.000 abstract 1
- 229940068968 polysorbate 80 Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
Abstract
A porous aluminum nanoparticulate structure comprising an aluminum salt, a capping agent and a water-soluble polymer from 0.001-2% of an adjuvant solution is disclosed. Moreover, the capping agent is selected from group consisting of Hydroxypropylbetacyclodextrin (HPBCD), Sulfobutyletherbetacyclodextrin (SBECD) or combination with water- soluble polymers such as PAA, Polysorbate 80 and further the capping agent is associated with the aluminum salt. Particularly, the size of the porous aluminum nanoparticulate ranges from about 1 nm to about 200 nm. Additionally the porous aluminum nanoparticulate structure is stable in a liquid formulation at about 0°C to about 8°C for at least about 1 month, at least about 6 months, or at least about 1 year. The disclosed technology further relates to compositions and methods of preparing a porous aluminum nanoparticulate structure.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163138873P | 2021-01-19 | 2021-01-19 | |
| US63/138,873 | 2021-01-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2022159319A2 WO2022159319A2 (en) | 2022-07-28 |
| WO2022159319A3 true WO2022159319A3 (en) | 2022-09-09 |
Family
ID=82549159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2022/012224 WO2022159319A2 (en) | 2021-01-19 | 2022-01-13 | A porous aluminum nanoparticulate structure |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2022159319A2 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080058427A1 (en) * | 2002-09-06 | 2008-03-06 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| US20150111838A1 (en) * | 2012-05-08 | 2015-04-23 | Onyx Therapeutics, Inc. | Cyclodextrin complexation methods for formulating peptide proteasome inhibitors |
| US20150307962A1 (en) * | 2014-04-23 | 2015-10-29 | Saint Louis University | Novel Hydrogen-Evolving Polymer-Capped Aluminum Nanoparticles, Composites, and Methods of Synthesis Using Lithium Aluminum Hydride |
| CN111701018A (en) * | 2020-06-22 | 2020-09-25 | 合肥诺为尔基因科技服务有限公司 | Cyclic dinucleotide modified aluminum nanoparticle vaccine adjuvant-delivery system |
| US11077134B1 (en) * | 2020-11-10 | 2021-08-03 | Mountain Valley Md Inc | Water dissolvable macrocyclic lactone cyclodextrin complexes |
-
2022
- 2022-01-13 WO PCT/US2022/012224 patent/WO2022159319A2/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080058427A1 (en) * | 2002-09-06 | 2008-03-06 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| US20150111838A1 (en) * | 2012-05-08 | 2015-04-23 | Onyx Therapeutics, Inc. | Cyclodextrin complexation methods for formulating peptide proteasome inhibitors |
| US20150307962A1 (en) * | 2014-04-23 | 2015-10-29 | Saint Louis University | Novel Hydrogen-Evolving Polymer-Capped Aluminum Nanoparticles, Composites, and Methods of Synthesis Using Lithium Aluminum Hydride |
| CN111701018A (en) * | 2020-06-22 | 2020-09-25 | 合肥诺为尔基因科技服务有限公司 | Cyclic dinucleotide modified aluminum nanoparticle vaccine adjuvant-delivery system |
| US11077134B1 (en) * | 2020-11-10 | 2021-08-03 | Mountain Valley Md Inc | Water dissolvable macrocyclic lactone cyclodextrin complexes |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022159319A2 (en) | 2022-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20062552L (en) | Process for the preparation of submicrometer-sized particles of paclitaxel | |
| PL1713446T3 (en) | Ternary non-lamellar lipid compositions | |
| MX352187B (en) | Composition of dexibuprofen transdermal hydrogel. | |
| AR076606A1 (en) | FORMULATIONS FOR ORAL CARE THAT INCREASE THE AMOUNT OF ZINC SOLUBLE | |
| Real et al. | Design, characterization, and in vitro evaluation of antifungal polymeric films | |
| WO2022159319A3 (en) | A porous aluminum nanoparticulate structure | |
| Gundogdu et al. | Comparison of cefpodoxime proxetil release and antimicrobial activity from tablet formulations: Complexation with hydroxypropyl-β-cyclodextrin in the presence of water soluble polymer | |
| JP2011063566A (en) | Ointment for oral cavity | |
| TW201720450A (en) | Ophthalmic composition | |
| JP2009179615A (en) | Antibacterial agent | |
| JP5205909B2 (en) | Mucosal fluid | |
| JP2006248960A (en) | Aqueous composition for external use | |
| Singh et al. | Physicochemical characterization of poly (ethylene glycol) plasticized poly (methyl vinyl ether‐co‐maleic acid) films | |
| JP5650397B2 (en) | Ophthalmic composition for silicone hydrogel contact lens | |
| Motiekaityte et al. | Antimicrobial dual‐cured photopolymers of vanillin alcohol diglycidyl ether and glycerol dimethacrylate | |
| JP2011207781A (en) | Ointment for oral cavity | |
| Zulfakar et al. | Development and mechanical characterization of eugenol–cetalkonium chloride sustained release mucoadhesive oral film | |
| JP2004123634A (en) | Ophthalmic composition | |
| JP2018512395A5 (en) | ||
| JP2007277233A (en) | Ophthalmic composition | |
| JP2008031165A (en) | Aqueous composition containing vitamin a compound | |
| JP2017165778A (en) | Ophthalmic composition for silicone hydrogel contact lens | |
| Mancuso et al. | Employment of indolebutyric and indoleacetic acids complexed by α-cydodextrin on cuttings rooting in Olea europaea L. cv. Leccio del Corno. Effects of concentration and treatment time | |
| JP2006104114A (en) | Mucous membrane application composition | |
| 박나래 et al. | The Preparation and Evaluation of Apigenin Nanoparticles for Antioxidant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22742997 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 22742997 Country of ref document: EP Kind code of ref document: A2 |